Rabéprazole Mylan Pharma
Rabéprazole Mylan Pharma Uses, Dosage, Side Effects, Food Interaction and all others data.
Rabéprazole Mylan Pharma Sodium is an antiulcerant drug in the class of Proton Pump Inhibitors. Rabéprazole Mylan Pharma Sodium is a substituted benzimidazole which suppresses gastric acid secretion by inhibiting the gastric H+/K+-ATPase enzyme at the secretory surface of the gastric parietal cell. It is an enteric coated tablet, because of its coated formulation it is highly stable in stomach and because of higher pKa value of Rabéprazole Mylan Pharma Sodium it provides faster onset of action. It blocks the final step of gastric acid secretion.
After oral administration of 20 mg, Rabéprazole Mylan Pharma is absorbed and can be detected in plasma by 1 hour. The effects of food on the absorption of Rabéprazole Mylan Pharma have not been evaluated. Rabéprazole Mylan Pharma is 96.3% bound to human plasma proteins. Rabéprazole Mylan Pharma is primarily metabolized in the liver by Cytochrome P-450 3A (Sulphone metabolite) and 2C19 (Desmethyl Rabéprazole Mylan Pharma). Following a single 20 mg oral dose of Rabéprazole Mylan Pharma, approximately 90% of the drug is eliminated in the urine.The remainder of the dose is excreted in the feaces.
Rabéprazole Mylan Pharma prevents the production of acid in the stomach. It reduces symptoms and prevents injury to the esophagus or stomach in patients with gastroesophageal reflux disease (GERD) or ulcers. Rabéprazole Mylan Pharma is also useful in conditions that produce too much stomach acid such as Zollinger-Ellison syndrome. Rabéprazole Mylan Pharma may also be used with antibiotics to get rid of bacteria that are associated with some ulcers. Rabéprazole Mylan Pharma is a selective and irreversible proton pump inhibitor, suppresses gastric acid secretion by specific inhibition of the H+, K+ -ATPase, which is found at the secretory surface of parietal cells. In doing so, it inhibits the final transport of hydrogen ions (via exchange with potassium ions) into the gastric lumen.
| Trade Name | Rabéprazole Mylan Pharma |
| Availability | Prescription only |
| Generic | Rabeprazole |
| Rabeprazole Other Names | Clofezone, Rabeprazole |
| Related Drugs | amoxicillin, omeprazole, famotidine, pantoprazole, metronidazole, Nexium, Pepcid, Protonix, esomeprazole, sucralfate |
| Type | |
| Formula | C18H21N3O3S |
| Weight | Average: 359.443 Monoisotopic: 359.130362243 |
| Protein binding | 96.3% (bound to human plasma proteins) |
| Groups | Approved, Investigational |
| Therapeutic Class | Proton Pump Inhibitor |
| Manufacturer | |
| Available Country | France |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Short-term treatment in healing and symptomatic relief of duodenal ulcers and erosive or ulcerative Gastroesophageal Reflux Disease (GERD).
Maintaining healing and reducing relapse rates of heartburn symptoms in patients with GERD.
Treatment of daytime and night time heartburn and other symptoms associated with GERD.
Long-term treatment of pathological hypersecretory conditions, including Zollinger Ellison Syndrome.
In combination with Amoxicillin and Clarithromycin to eradicate Helicobacter pylori.
Rabéprazole Mylan Pharma is also used to associated treatment for these conditions: Duodenal Ulcer, Gastric Ulcer, Gastro-esophageal Reflux Disease (GERD), Heartburn, Helicobacter Pylori Infection, NSAID Associated Gastric Ulcers, Non-erosive Reflux Esophagitis Disease (NERD), Vomiting, Zollinger-Ellison Syndrome, Erosive reflux esophagitis
How Rabéprazole Mylan Pharma works
Rabéprazole Mylan Pharma belongs to a class of antisecretory compounds (substituted benzimidazole proton-pump inhibitors) that do not exhibit anticholinergic or histamine H2-receptor antagonist properties, but suppress gastric acid secretion by inhibiting the gastric H+/K+ATPase (hydrogen-potassium adenosine triphosphatase) at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, rabeprazole has been characterized as a gastric proton-pump inhibitor. Rabéprazole Mylan Pharma blocks the final step of gastric acid secretion. In gastric parietal cells, rabeprazole is protonated, accumulates, and is transformed to an active sulfenamide. When studied in vitro, rabeprazole is chemically activated at pH 1.2 with a half-life of 78 seconds.
Dosage
Rabéprazole Mylan Pharma dosage
Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD): 20 mg to be taken once daily for 4 to 8 weeks. For those patients who have not healed after 8 weeks of treatment, an additional 8 week course may be considered.
Maintenance of Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD Maintenance): The recommended adult oral dose is 20 mg once daily.
Treatment of Symptomatic Gastroesophageal Reflux Disease (GERD):The recommended adult oral dose is 20 mg once daily for 4 weeks. If symptoms do not resolve completely after 4 weeks, an additional course of treatment may be considered.
Healing of Duodenal Ulcers:The recommended adult oral dose is 20 mg once daily after the morning meal for a period up to four weeks. Most patients with duodenal ulcer heal within four weeks. A few patients may require additional therapy to achieve healing.
Helicobacter pylori Eradication:To Reduce the Risk of Duodenal Ulcer Recurrence-
- Rabéprazole Mylan Pharma Sodium 20 mg Twice Daily for 7 Days
- Amoxicillin 1000 mg Twice Daily for 7 Days
- Clarithromycin 500 mg Twice Daily for 7 Days
All three medications should be taken twice daily with the morning and evening meals. It is important that patients comply with the full 7-day regimen.
Treatment of Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome: The dosage of Rabéprazole Mylan Pharma Sodium in patients with pathologic hypersecretory conditions varies with the individual patient. The recommended adult oral starting dose is 60 mg once a day. Doses should be adjusted to individual patient needs and should continue for as long as clinically indicated. Some patients may require divided doses. Doses up to 100 mg QD and 60 mg BID have been administered. Some patients with Zollinger-Ellision syndrome have been treated continuously with Rabéprazole Mylan Pharma Sodium for up to one year.
Side Effects
Rabéprazole Mylan Pharma Sodium may sometimes cause headache, diarrhoea, abdominal pain, vomiting, constipation, dry mouth, increased or decreased appetite, muscle pain, drowsiness and dizziness.
Precaution
Administration of Rabéprazole Mylan Pharma Sodium to patients with mild to moderate liver impairment resulted in increased exposure and decreased elimination. Caution should be exercised in patients with severe hepatic impairment.
Interaction
Rabéprazole Mylan Pharma is metabolized by the Cytochrome P-450 (CYP-450) drug metabolizing enzyme system. Rabéprazole Mylan Pharma does not have clinically significant interactions with other drugs metabolized by the CYP-450 system,such as Warfarin and Theophylline given as single oral dose, Diazepam as a single intravenous dose, and Phenytoin given as a single intravenous dose. In normal subjects, co-administration of Rabéprazole Mylan Pharma 20 mg QD resulted in an approximately 30% decrease in the bioavailability of Ketoconazole and increase in the AUC and Cmax for digoxin of 90% and 29% respectively.
Food Interaction
- Take with or without food. Food delays drug absorption, but not to a clinically significant extent.
Rabéprazole Mylan Pharma Drug Interaction
Major: clopidogrelModerate: levothyroxineMinor: aspirin, aspirin, duloxetine, cyanocobalaminUnknown: celecoxib, rosuvastatin, apixaban, omega-3 polyunsaturated fatty acids, atorvastatin, pregabalin, metoprolol, metoprolol, acetaminophen, budesonide / formoterol, ascorbic acid, cholecalciferol, bupropion, cetirizine
Rabéprazole Mylan Pharma Disease Interaction
Major: C. diffModerate: bone fractures, hypomagnesemia, liver disease
Elimination Route
Absolute bioavailability is approximately 52%.
Half Life
1-2 hours (in plasma)
Elimination Route
Following a single 20 mg oral dose of 14C-labeled rabeprazole, approximately 90% of the drug was eliminated in the urine, primarily as thioether carboxylic acid; its glucuronide, and mercapturic acid metabolites.
Pregnancy & Breastfeeding use
Rabéprazole Mylan Pharma is FDA Pregnancy Category B. No data is available on administration of Rabéprazole Mylan Pharma to pregnant women. However this drug should be used during pregnancy, only if clearly needed. There are no data on the excretion of Rabéprazole Mylan Pharma into the breast milk. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the benefit of the drug to the mother.
Contraindication
Rabéprazole Mylan Pharma Sodium is contraindicated in patient with known hypersensitivity to Rabéprazole Mylan Pharma or to any component in the product.
Special Warning
Use in pediatric patients: The safety and effectiveness of Rabéprazole Mylan Pharma in pediatric patients have not been established.
Acute Overdose
There has been no experience with large overdoses with Rabéprazole Mylan Pharma. No specific antidote for Rabéprazole Mylan Pharma is known. Rabéprazole Mylan Pharma is extensively protein bound and is not readily dialyzable. In the event of overdosage, treatment should be symptomatic and supportive.
Storage Condition
Store below 25°C, protected from light and moisture. Keep all medicines out of the reach of the children.
Innovators Monograph
You find simplified version here Rabéprazole Mylan Pharma
Rabéprazole Mylan Pharma contains Rabeprazole see full prescribing information from innovator Rabéprazole Mylan Pharma Monograph, Rabéprazole Mylan Pharma MSDS, Rabéprazole Mylan Pharma FDA label
FAQ
What is Rabéprazole Mylan Pharma used for?
Rabéprazole Mylan Pharma used for heartburn, acid reflux and gastro-oesophageal reflux disease when you keep getting acid reflux. Rabéprazole Mylan Pharma is also taken to prevent and treat stomach ulcers. Rabéprazole Mylan Pharma reduces the amount of acid your stomach makes.
How safe is Rabéprazole Mylan Pharma?
Rabéprazole Mylan Pharma is efficacious in gastro-esophageal reflux disease (GERD) and other acid-related diseases. Long-term use of Rabéprazole Mylan Pharma was confirmed to be safe in studies of two to five-year maintenance therapy for GERD.
What are side effects of Rabéprazole Mylan Pharma?
Common side effects may include:
- infection;
- pain;
- sore throat;
- headache;
- nausea, vomiting;
- gas, diarrhea, constipation; or.
- stomach pain.
Is Rabéprazole Mylan Pharma taken empty stomach?
Rabéprazole Mylan Pharma can be taken either before or after food, although taking it before food is preferable. If you forget to take a dose at your usual time, you can generally take it when you remember.
Is Rabéprazole Mylan Pharma safe for my kidneys?
Rabéprazole Mylan Pharma can cause kidney problems.If you have blood in your urine. Diarrhea may be a sign of a new infection.
Is Rabéprazole Mylan Pharma safe during pregnancy?
Rabéprazole Mylan Pharma isn't usually recommended during pregnancy as there's no firm evidence it's safe. if you're pregnant, it's better to try to treat symptoms of acid reflux and heartburn without taking a medicine.
Is Rabéprazole Mylan Pharma safe to take while breastfeeding?
The SPC advises to avoid the use of rabeprazole during lactation.levels for both drugs are low, and in addition a large proportion of any of the drug ingested by the infant is likely to be destroyed by the acid in the stomach.
Does Rabéprazole Mylan Pharma work right away?
Rabéprazole Mylan Pharma starts doing its job within an hour of taking the first dose, you may not feel that your symptoms have improved for several days. This is because Rabéprazole Mylan Pharma has to “turn off” the proton pumps of the acid-producing cells in the stomach, and it is not able to turn off all proton pumps immediately.
How long Rabéprazole Mylan Pharma can be taken?
Rabéprazole Mylan Pharma is for short-term use only, usually 4 to 8 weeks. Your doctor may recommend a second course of treatment if you need additional healing time.
Is Rabéprazole Mylan Pharma good for gastritis?
Rabéprazole Mylan Pharma may good to treat: Reflux oesophagitis. Peptic ulcers. Chronic Gastritis.
Can Rabéprazole Mylan Pharma cause liver problems?
Rabéprazole Mylan Pharma therapy is associated with a low rate of transient and asymptomatic serum aminotransferase elevations and is a rare cause of clinically apparent liver injury.
Is Rabéprazole Mylan Pharma safe long term?
The drug is efficacious in gastro-esophageal reflux disease (GERD) and other acid-related diseases. Long-term use of Rabéprazole Mylan Pharma was confirmed to be safe in studies of two to five-year maintenance therapy for GERD.
What happens when you stop taking Rabéprazole Mylan Pharma?
Stopping the Rabéprazole Mylan Pharma suddenly could make your stomach produce a lot more acid, and make your symptoms return.you can stop taking rabeprazole without reducing the dose first. If you've taken Rabéprazole Mylan Pharma for a long time, speak to your doctor before you stop taking Rabéprazole Mylan Pharma.
Is Rabéprazole Mylan Pharma an antifungal?
Proton pump inhibitors, such as Rabéprazole Mylan Pharma act as agents with antifungal activity or reverse-acquired resistance to azoles.
Is Rabéprazole Mylan Pharma a controlled substance?
Rabéprazole Mylan Pharma 20 mg is not a controlled substance under the Controlled Substances Act (CSA).
What class of drug is Rabéprazole Mylan Pharma?
Rabéprazole Mylan Pharma is in a class of medications called proton-pump inhibitors.
Can you take Tylenol with Rabéprazole Mylan Pharma?
No interactions were found between Rabéprazole Mylan Pharma and Tylenol. This does not necessarily mean no interactions exist. Always consult your healthcare provider.
How many Rabéprazole Mylan Pharma Can I take a day?
Adults can take Rabéprazole Mylan Pharma 20 milligrams (mg) once a day for up to 4 weeks. Your doctor may adjust your dose as needed. Children 12 years of age and older take Rabéprazole Mylan Pharma 20 mg once a day for up to 8 weeks. Your child's doctor may adjust the dose as needed.
